Journal article
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
Abstract
BACKGROUND: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.
METHODS: In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, …
Authors
Connolly SJ; Ezekowitz MD; Yusuf S; Eikelboom J; Oldgren J; Parekh A; Pogue J; Reilly PA; Themeles E; Varrone J
Journal
The New England Journal of Medicine, Vol. 361, No. 12, pp. 1139–1151
Publisher
Massachusetts Medical Society
Publication Date
September 17, 2009
DOI
10.1056/nejmoa0905561
ISSN
0028-4793